Fig. 1: Effects of semaglutide compared to placebo across different obesity classes on HF symptoms, physical limitations and body weight. | Nature Medicine

Fig. 1: Effects of semaglutide compared to placebo across different obesity classes on HF symptoms, physical limitations and body weight.

From: Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Fig. 1

a,b, There was no evidence of heterogeneity in the effects of semaglutide compared to placebo on the dual primary endpoints of KCCQ-CSS (a) or body weight (b). Data are point estimates and 95% CIs. Analyses using the intention-to-treat principle employ an F-test for interaction and a Wald test for treatment effect within BMI subgroups, with 1,000 imputations using Rubin’s rule. Analyses using on-treatment data employ an F-test for interaction and a t-test for treatment effect within BMI subgroups. P values are two-sided. ETD, estimated treatment difference.

Back to article page